https://ijpcr.net/ijpcr <p><strong><em>International Journal of Pharmacology and Clinical Research (IJPCR) </em></strong>is a peer-reviewed, quarterly official international journal allowing access to abstracts<strong>&nbsp;</strong>and<strong>&nbsp;</strong>full-text. The journal is devoted to the promotion of pharmaceutical sciences and related disciplines (Pharmacology, Biopharmaceutics, Pharmacokinetics, Pharmaceutical Medicinal Chemistry, Computational Chemistry &amp; Molecular Drug Design, Pharmacognosy &amp; Phytochemistry, Pharmaceutical Analysis, Pharmacy Practice, Clinical &amp; Hospital Pharmacy, Cell Biology, Genomics &amp; Proteomics, Pharmacogenomics, Bioinformatics including biotechnology, cell &amp; molecular biology, Pharmaceutical biotechnology/microbiology, medical and other life sciences).</p> <p><strong>ISSN</strong>&nbsp;-&nbsp;<strong><em>International Journal of Pharmacology and Clinical Research (IJPCR)</em></strong></p> <p><strong>Online</strong>:<strong>&nbsp;</strong>2521-2206</p> <p><strong><em>International Journal of Pharmacology and Clinical Research </em></strong>seeks to foster multidisciplinary research and collaboration among scientists, pharmaceutical industries and healthcare sector as well as provide an international forum for the communication and evaluation of data, methods and opinions in pharmaceutical sciences and related disciplines. Although primarily devoted to original research papers, the journal particularly welcomes reviews on current topics of special interest and relevance. All manuscripts will be subjected to rapid peer review. Those of high quality (not previously published and not already under consideration for publication) will be published.</p> Dr.N.Sriram en-US International Journal of Pharmacology and Clinical Research (IJPCR) 2521-2206 https://ijpcr.net/ijpcr/article/view/579 <p>Schizophrenia is a debilitating psychiatric disorder characterized by psychotic symptoms, including hallucinations and delusions, which profoundly impact emotions, behavior, and cognition. Its global prevalence underscores its significance as a public health concern, with substantial social and economic burdens. The pathophysiology of schizophrenia implicates dysregulation of neurotransmitters, particularly dopamine, serotonin, and glutamate. Schizophrenia is a complex psychiatric disorder characterized by a wide range of symptoms and cognitive impairments, profoundly impacting affected individuals and society. This article provides an overview of schizophrenia, including its epidemiology, symptoms, and underlying pathophysiology involving dopamine, serotonin, and glutamate. It discusses the current treatment landscape, emphasizing the importance of both pharmacological and non-pharmacological interventions. Non-pharmacological approaches such as cognitive remediation, physical exercise, non-invasive brain stimulation, complementary interventions, cognitive behavioral therapy, and yoga therapy are explored, highlighting their efficacy in improving functional outcomes. Additionally, the article reviews pharmacological strategies targeting dopamine, serotonin, and glutamate receptors, as well as emerging treatments involving adrenergic, cholinergic, muscarinic, and other agents. Despite advancements, challenges in implementing evidence-based interventions persist, underscoring the need for further research and collaboration to enhance schizophrenia management and improve the lives of affected individuals.</p> Amna Hameed Thayyil Zeenath P Aiswarya Lakshmi P E Tamil Jothi G Babu Anson S Maroky Copyright (c) 2024-04-15 2024-04-15 8 2 138 146 https://ijpcr.net/ijpcr/article/view/580 <p>Numerous observational studies conducted in the past few years have confirmed the link between statin use and colorectal cancer by preserving and lowering the death rate. Statins may have an impact on cancer cells' ability to proliferate, migrate, and survive. Since the 1990s, the idea of utilizing statins to treat cancer has gained traction. Statins have been used in cohort studies, in vitro and in vivo tests, and on tumor-related inflammation and oxidative stress to show their anticancer effects. Method: we systematically searched for studies about the statin used in colorectal cancer patients in electronic databases, including PubMed, Web of Science, academic Google Scholar, and science direct, covering the last eight years up until 2022. A total of 8 studies, which include 506,346 individuals, of whom, 100,225 were statins users. The collected data assessed by using Statistical Package for the Social Sciences (SPSS). Result: Our analysis selected studies presented with outcome based on relative ratios (RRs) and 95% confidence intervals (CIs) of colorectal cancer-specific mortality. The use of statin was potentially associated with a decline in colorectal cancer-specific mortality in cancer patients (RR; 0.92; 95% CI, 0.90 to 0.95; random-effects model: RR0.90; 95% CI, 0.79 to 0.96). The meta-analysis showed that ongoing statin therapy was associated with a 20% decrease in the risk of colorectal cancer-specific mortality compared to patients without ongoing statin therapy (adjusted HR 0.75, 95%CI 0.65-0.85, P &lt; .002). Conclusion: The risk of colorectal cancer was lower in statin user versus nonuser, accumulating evidence suggests that statins may have a role in colorectal cancer prevention and treatment. Among Lipid lowering medication (LLM) users, adherence to this drug is associated with a decrease in cancer-specific mortality.</p> Reyad Al-Moktar Ekhmaj Wafa Mahmoud Alshaiby Einass Ragab Ibraheim Copyright (c) 2024-04-19 2024-04-19 8 2 147 155